CING

Company Overview — What Does Cingulate Inc. Do?

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey. Cingulate Inc. (CING) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Shane J. Schaffer and employs approximately 20 people. With a market capitalization of $70M, CING is one of the notable companies in the Healthcare sector.

Cingulate Inc. (CING) Stock Rating — Reduce (April 2026)

As of April 2026, Cingulate Inc. receives a Reduce rating with a composite score of 31.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CING ranks #3,432 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Cingulate Inc. ranks #530 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CING Stock Price and 52-Week Range

Cingulate Inc. (CING) currently trades at $5.86. The stock lost $0.10 (1.7%) in the most recent trading session. The 52-week high for CING is $11.89, which means the stock is currently trading -50.7% from its annual peak. The 52-week low is $3.20, putting the stock 83.1% above its annual trough. Recent trading volume was 301K shares, suggesting relatively thin trading activity.

Is CING Overvalued or Undervalued? — Valuation Analysis

Cingulate Inc. (CING) carries a value factor score of 17/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 27.53x, versus the sector average of 2.75x.

At current multiples, Cingulate Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Cingulate Inc. Profitability — ROE, Margins, and Quality Score

Cingulate Inc. (CING) earns a quality factor score of 8/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -773.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -128.8% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CING Debt, Balance Sheet, and Financial Health

Cingulate Inc. has a debt-to-equity ratio of 501.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.16x, suggesting adequate working capital coverage. Total debt on the balance sheet is $3M. Cash and equivalents stand at $6M.

CING has a beta of 0.98, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Cingulate Inc. is 30/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Cingulate Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Cingulate Inc. reported revenue of $-233,714 and earnings per share (EPS) of $-4.44. Net income for the quarter was $-19M. Operating income came in at $-18M.

In FY 2025, Cingulate Inc. reported revenue of $-1M and earnings per share (EPS) of $-4.44. Net income for the quarter was $-22M. Operating income came in at $-20M.

In Q3 2025, Cingulate Inc. reported revenue of N/A and earnings per share (EPS) of $-1.35. Net income for the quarter was $-7M. Operating income came in at $-6M.

In Q2 2025, Cingulate Inc. reported revenue of $-136,930 and earnings per share (EPS) of $-1.09. Net income for the quarter was $-5M. Operating income came in at $-5M.

Over the past 8 quarters, Cingulate Inc. has reported varying levels of revenue. Investors analyzing CING stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CING Dividend Yield and Income Analysis

Cingulate Inc. (CING) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CING Momentum and Technical Analysis Profile

Cingulate Inc. (CING) has a momentum factor score of 68/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 37/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

CING vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Cingulate Inc. (CING) ranks #530 out of 838 stocks based on the Blank Capital composite score. This places CING in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CING against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CING vs S&P 500 (SPY) comparison to assess how Cingulate Inc. stacks up against the broader market across all factor dimensions.

CING Next Earnings Date

No upcoming earnings date has been announced for Cingulate Inc. (CING) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CING? — Investment Thesis Summary

The quantitative profile for Cingulate Inc. suggests caution. The quality score of 8/100 flags below-average profitability. The value score of 17/100 indicates premium valuation. Price momentum is positive at 68/100, suggesting the trend favors buyers. High volatility (stability score 30/100) increases portfolio risk.

In summary, Cingulate Inc. (CING) earns a Reduce rating with a composite score of 31.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CING stock.

Related Resources for CING Investors

Explore more research and tools: CING vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CING head-to-head with peers: CING vs AZN, CING vs SLGL, CING vs VMD.